Imfinzi 500mg Injection

Like most anticancer drugs, Imfinzi 500mg Injection may cause some adverse effects on the body during the treatment. These can vary from mild to severe depending on the dose and the patient’s health condition. Inform your doctor immediately if you experience any persistent or unusual side effects. Side effects include:

• ​Cough
  
• Upper respiratory tract infections
  
• Fatigue / tiredness
  
• Rash
  
• Hair loss
  
• Diarrhea
  
• Itching
  
• Abdominal pain
  
• Musculoskeletal pain (bones, muscles, joints)
  
• Muscle pain (myalgia)
  
• Hoarse voice (dysphonia)
  
• Night sweats
  
• Shortness of breath / breathlessness
  
• Pneumonitis (lung inflammation)
  
• Pneumonia (serious lung infection)
  
• General infections (chills, fever)
  
• Fungal infection in the mouth
  
• Tooth and mouth soft tissue infections
  
• Flu-like illness
  
• Abnormal liver tests (AST/ALT increased)
  
• Abnormal kidney function tests (blood creatinine increased)
  
• Painful urination
  
• Swelling of the legs (peripheral edema)
  
• Overactive thyroid (fast heart rate, weight loss)
  
• Infusion reactions (fever, flushing)
  

• Imfinzi 500mg Injection should be given intravenously by a doctor or experienced nurse under strict medical supervision.
• It is not intended for self-administration.
• The doctor will determine the appropriate dosage and duration of treatment based on the type and stage of cancer, as well as the patient's health condition.
• It can be used alone or in combination with other medicines during the treatment.

• In case you missed a dose of Durvalumab injection, immediately contact your doctor. 

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Dewi, I. G. A. G. S., Putri, L. A. L. N., Silalahi, L. D., Widha, I. G. A., Dewi, P., Hapsari, M. D., ... & Warditiani, N. K. (2025). Systematic Literature Review on Sterile Injectable Dates of Use, Stability and Implications for Use. Svāsthya: Trends in General Medicine and Public Health, 2(1), e66-e66 - https://journal.megsci-ind.org/index.php/Svasthya/article/view/66
  
• Paik, P. K., Luo, J., Ai, N., Kim, R., Ahn, L., Biswas, A., ... & Kris, M. G. (2022). Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nature Communications, 13(1), 6095 - https://www.nature.com/articles/s41467-022-33719-6
  
• Al-Salama, Z. T. (2021). Durvalumab: a review in extensive-stage SCLC. Targeted Oncology, 16(6), 857-864 - https://pubmed.ncbi.nlm.nih.gov/34731446/
  
• Almasi, J., Thiesen, J., & Krämer, I. (2023). Physicochemical stability of durvalumab (Imfinzi®) concentrate for solution in original vials after first opening. Pharmaceutical Technology in Hospital Pharmacy, 8(1), 20230008 - https://www.degruyterbrill.com/document/doi/10.1515/pthp-2023-0008/html
  
• Day-Storms, J. (2023). IMJUDO (Tremelimumab-actl) in Combination With IMFINZI (Durvalumab) Receives FDA Approval for HCC and NSCLC - https://www.ahdbonline.com/issues/2023/september-2023-vol-16-payers-guide/imjudo-tremelimumab-actl-in-combination-with-imfinzi-durvalumab-receives-fda-approval-for-hcc-and-nsclc
  
• Rashid, M. A. (2023). New Indications & Dosage Forms for Existing Drugs Vol. 26 (1). Bangladesh Pharmaceutical Journal, 26(1), 114-118 - https://www.banglajol.info/index.php/BPJ/article/view/71454/47793